Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10034906-B2
Publication Date
2018-07-31
Expiration Date
Abstract
There is provided a composition comprising a polysaccharide obtainable from the microalgae, Prasinococcus capsulatus and strains related to P. capsulatus for use in the treatment of disorders of the immune system, for example in psoriasis and dermatological conditions, internal immune system disorders, in particular gut inflammatory conditions and respiratory conditions. Further, there is provided derivatives of a polysaccharide obtainable from the microalgae, Prasinococcus capsulatus or an algal strain related to P. capsulatus and the use of such derivatives in the treatment of disorders of the immune system.
Core Innovation
The invention provides a method of treating a disorder of the immune system by administering a gel forming polysaccharide to a subject in need thereof. The gel forming polysaccharide is obtainable from microalgal cells from the order Prasinococcales. The gel forming polysaccharide is a sulfated heteropolymer with molecular weight of at least 670 kDa, comprising glucose, galactose, arabinose and uronic acid units.
The polysaccharide is described with compositional and functional characteristics that relate to immunomodulatory activity. Characterization targets include monosaccharide makeup comprising glucose, galactose, arabinose and uronic acids, and a sulfate content range stated as about 17% to 35% by weight. Functional immunomodulation described includes inhibition of neutrophil elastase activity and reduction of neutrophil reactive oxygen species, as well as suppression of keratinocyte cytokines including IL-8.
Further immune-system modulation described includes reduction of PBMC IFN-γ, inhibition of neutrophil and monocyte chemotaxis, reduced IL-6 and IL-17C release, and reduction of imiquimod-induced mouse skin inflammation. The disclosure also addresses oligosaccharide derivatives and formulations, including nutritional supplements and cosmetic preparations, as part of using the polysaccharide and related derivatives.
Claims Coverage
The partial content identifies one independent claim directed to a treatment method using a Prasinococcales-derived gel forming sulfated heteropolymer polysaccharide of defined composition and molecular weight. Dependent claims refine the polysaccharide source, specify immune disorder targets, and add quantitative composition and functional activity constraints, including sulfate content and neutrophil elastase inhibition.
Treating immune system disorders with Prasinococcales gel-forming sulfated heteropolymer polysaccharide
A method of treating a disorder of the immune system comprising administering a gel forming polysaccharide to a subject in need thereof, wherein the gel forming polysaccharide is obtainable from microalgal cells from the order Prasinococcales, and wherein the gel forming polysaccharide is a sulfated heteropolymer of molecular weight of at least 670 kDa comprising glucose, galactose, arabinose and uronic acid units.
Neutrophil elastase inhibition by the polysaccharide
The method covers treating an immune-system disorder using a polysaccharide that inhibits neutrophil elastase activity in neutrophils by about 60% to 90% compared with neutrophils not provided the polysaccharide.
Sulfated heteropolymer with a defined sulfate content range
The method includes using a polysaccharide having a sulfate content of about 17 to 35% by weight.
Defining monosaccharide and uronic acid composition ranges
The method for treating an immune-system disorder includes administering a gel-forming polysaccharide with about 20 to 30% glucose, 30 to 60% galactose, 4 to 19% arabinose, 2 to 6% uronic acids, and 1 to 10% other sugar units.
Obtaining the polysaccharide by culturing Prasinococcales cells and extracting secreted polysaccharide
The method treats an immune-system disorder by producing a microalgal polysaccharide through culturing Prasinococcales microalgal cells and extracting the secreted microalgal polysaccharide from the culture medium.
Treating specified inflammatory skin, gut, or respiratory immune disorders
The claim covers a method for treating an immune-system disorder, where the disorder is selected from specified inflammatory skin, gut, or respiratory conditions.
Across the identified claims, the core inventive concept is administering a Prasinococcales obtainable gel forming sulfated heteropolymer polysaccharide with molecular weight of at least 670 kDa comprising glucose, galactose, arabinose and uronic acid units, with refinements that specify obtaining, target inflammatory immune disorders, compositional constraints, and a functional constraint of neutrophil elastase inhibition.
Stated Advantages
Inhibits neutrophil elastase activity.
Reduces neutrophil reactive oxygen species.
Suppresses keratinocyte cytokines including IL-8.
Reduces PBMC IFN-γ.
Inhibits neutrophil and monocyte chemotaxis.
Reduces IL-6 and IL-17C release.
Reduces imiquimod-induced mouse skin inflammation.
Documented Applications
Prophylactic/therapeutic treatment of inflammatory immune-system disorders in skin, including psoriasis, eczema, and atopic dermatitis.
Prophylactic/therapeutic treatment of inflammatory immune-system disorders in the gut, including irritable bowel syndrome, Crohn’s disease, and ulcerative colitis.
Prophylactic/therapeutic treatment of inflammatory immune-system disorders in the respiratory system, including asthma, COPD, ARDS, cystic fibrosis, and allergic rhinitis.
Use in nutritional supplement formulations.
Use in cosmetic preparation formulations.
Interested in licensing this patent?